Endocrine Fellows: T1DM 2021 Caring for the Sick Patient at Home and in Emergency Situations

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Educator/Teacher
Nurse/Nurse practitioner
Competency Area: 
Professionalism
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Interpersonal and Communication Skills
Topic Area: 
Diabetes and Glucose Metabolism
Quality Improvement and Healthcare Delivery
General Endocrinology
Pediatric Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Course opens: 
03/20/2021
Course expires: 
03/20/2022
Rating: 
0

T1D Fellows Program On-Demand Courses

Keynote: Looking Back at 100 Years of Insulin

  • Jay S. Skyler, MD, University of Miami 

Diagnosing and Understanding Risks of T1D

  • Challenging Cases in the Diagnosis of T1D
    • Irl B. Hirsch, MD, University of Washington
  • Hypoglycemia in T1D: Risks and Practical Prevention Strategies
    • Elizabeth Seaquist, MD, University of Minnesota

Principles in Insulin and Emerging Non-Insulin Therapies 

  • A Fresh Look at Insulin Therapy
    • Irl B. Hirsch, MD, University of Washington
  • Optimizing Multiple Daily Injection Therapy
    • Satish Garg, MD, Barbara Davis Center
  • Going Beyond Insulin: Updates on Non-Insulin Options for T1D
    • Anne Peters, MD, USC Westside Center for Diabetes

Closing the Loop with Diabetes Technology

  • Practical Considerations and Approaches to Data Management
    • Irl B. Hirsch, MD, University of Washington
  • Insights into Insulin Pump Therapy
    • Janet McGill, MD, MA, FACE, Washington University in St. Louis
  • Interpreting CGM with Your Patients
    • Davida F. Kruger, MSN, APN-BC, BC-ADM, Henry Ford Health System

Screening, Preventing, and Treating Vascular Disease

  • T1D and the Prevention and Treatment of Macrovascular Disease
    • Robert H. Eckel, MD, University of Colorado
  • The Endocrinologist’s Role in Screening/Managing Microvascular Disease
    • Janet McGill, MD, MA, FACE, Washington University in St. Louis

Addressing Depression in T1D and Challenges across the Lifespan

  • Identifying and Confronting Challenging Transitions
    • Linda Siminerio, PhD, University of Pittsburgh
  • Developmental Perspectives in the Psychosocial Aspects of Diabetes
    • Jill A. Weissberg-Benchell, PhD, CDE, Northwestern University

Nutrition and Exercise in T1D Management 

  • Implementing Realistic Nutrition Strategies
    • Alison B. Evert, MS, RD, CDE, University of Washington
  • Exercise Management: Considerations and Strategies for T1D
    • Michael C. Riddell, PhD, York University

Caring for the Sick Patient at Home and in Emergency Situations 

  • Managing the Sick Patient at Home
    • Jennifer Sherr, MD, PhD, Yale School of Medicine

PROGRAM DIRECTORS

Irl B. Hirsch, MD, University of Washington School of Medicine

Davida F. Kruger, MSN, APN-BC, BC-ADM, Henry Ford Health System

 

PRESENTERS

Luisa Duran, MD, John Muir Health

Robert H. Eckel, MD, University of Colorado

Alison B. Evert, MS, RD, CDE, University of Washington

Satish Garg, MD, Barbara Davis Center

Janet B. McGill, MD, MA, FACE, Washington University in St. Louis

Michael C. Riddell, PhD, York University

Elizabeth Seaquist, MD, University of Minnesota

Jennifer Sherr, MD, PhD, Yale School of Medicine

Linda M. Siminerio, RN, PhD, CDE, University of Pittsburgh

Jill A. Weissberg-Benchell, PhD, CDE, Northwestern University

Jay S. Skyler, MD, University of Miami

 

STATEMENT OF INDEPENDENCE

As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society's Special Programs Committee (SPC). The commercial supporter(s) of this activity have no influence over the planning of this CME activity.

 

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported the following relevant financial relationship(s) during the content development process for this activity:

 Irl B. Hirsch, MD (Co-Chair), has served as a research investigator for Beta Bionics, Medtronic Diabetes and Insulet and as a consultant/advisory board for Abbot Diabetes Care and Big Foot Biomedical.

Davida F. Kruger, MSN, APN-BC, BC-ADM (Co-Chair), has served on advisory boards and/or speaker bureaus for Abbott Diabetes Care, Dexcom, Eli Lilly and Company, Novo Nordisk, Pendulum Life, sanofi-aventis U.S. LLC, and Xeris.

Robert H. Eckel, MD, has served as a consultant and/or advisory board member to Kaleido Biosciences, Kowa American Corp., and Provention Bio, Inc.

Satish Garg, MD, has served on the advisory board for Novo Nordisk, Inc., Zealand, Medtronic, and Eli Lilly.

Janet B. McGill MD, MA, has received grant funding from Dexcom, Medtronic, and Novo Nordisk; has served as a consultant and/or advisory board for Bayer, Boehringer Ingelheim, Dexcom, Lilly, Metavant, Salix.

Anne L. Peters, MD, has served on an advisory board for Abbot Diabetes Care, Eli Lilly, Medscape, Merck, Novo Nordisk, Zealand; lecturer for Biorad; and received research funding from Dexcom.

Michael C. Riddell, PhD, has served as a consultant for Insulet Corporation, advisory board for Zucara Theraputics, received honoraria for Speakers' Bureau for Novo Nordisk, Eli Lilly, and Sanofi.

Jennifer Sherr, MD, PhD, has served as a consultant and/or advisory board member for Insulet, Lexicon, Bigfoot Biomedical, Cecelia Health and received research support from Medtronic Diabetes, Lilly Diabetes

Linda M. Siminerio, RN, PhD, CDE, has received research support from Becton Dickinson and Sanofi, and served on the advisory board for Abbott and Bayer.

The following faculty reported no relevant financial relationship: Luisa Duran, MD, Alison B. Evert, MS, RD, CDE, Elizabeth Seaquist, MD, and Jill A. Weissberg-Benchell, PhD, CDE, Jay S. Skyler, MD.

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
 

DISCLAIMER

The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

 

Use of professional judgment:

The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

 

Drugs and dosages:

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

 

POLICY ON UNLABELED/OFF-LABEL USE

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

 

PRIVACY AND CONFIDENTIALITY STATEMENT

The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

 

COMMERCIAL SUPPORT

This education activity is supported by an independent medical educational grant from Abbott Diabetes Care, Inc., Dexcom, Inc., Helmsley Charitable Trust, Insulet Corporation, Lilly USA, Medtronic Diabetes, and Tandem Diabetes Care.